Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer

British Journal of Pharmacology

Volumn 173, Issue 23, 2016, Pages 3292-3306

  Coothankandaswamy, V ^a   Cao, S ^b   Xu, Y ^b   Prasad, P D ^a   Singh, P K ^c   Reynolds, C P ^d   Yang, S ^d   Ogura, J ^d   Ganapathy, V ^d   Bhutia, Y D ^d  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b University of Georgia   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; MESSENGER RNA; N METHYLTRYPTOPHAN; PROTEIN SLC6A14; UNCLASSIFIED DRUG; ALPHA-METHYLTRYPTOPHAN; ANTINEOPLASTIC AGENT; SLC6A14 PROTEIN, HUMAN; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KWASHIORKOR; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA ANALYSIS; TUMOR XENOGRAFT; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; RNA, MESSENGER; TRYPTOPHAN; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84994218615     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13616     Document Type: Article

References (48)

1. Abraham RT (2004). mTOR as a positive regulator of tumor cell responses to hypoxia. Curr Top Microbiol Immunol 279: 299–319.
2. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
3. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110–6202.
4. Altomare DA, Khaled AR (2012). Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. Curr Med Chem 19: 3748–3762.
5. Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W et al. (2009). Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand J Gastroenterol 44: 782–786.
6. Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I (2008). Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology 55: 2016–2027.
7. Barry S, Chelala C, Lines K, Sunamura M, Wang A, Marelli-Berg FM et al. (2013). S100P is a metastasis-associated gene that facilitates transendothelial migration of pancreatic cancer cells. Clin Exp Metastasis 30: 251–264.
8. Bhutia YD, Ganapathy V (2015). Glutamine transporters in mammalian cells ad their function in physiology and cancer. Biochim Biophys Acta. doi:10.1016/j.bbamcr.2015.12.017.
9. Bhutia YD, Babu E, Prasad PD, Ganapathy V (2014). The amino acid transporter SLC6A14 in cancer and its potential use in chemotherapy. Asian J Pharm Sci 9: 293–303.
10. Bhutia YD, Babu E, Ramachandran S, Ganapathy V (2015). Amino acid transporters in cancer and their relevance to “glutamine addiction”: novel targets for the design of a new class of anticancer drugs. Cancer Res 75: 1782–1788.
11. Chaika NV, Yu F, Purohit V, Mehla K, Lazenby AJ, DiMaio D et al. (2012). Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. PLoS One 7: e32996.
12. Chugani DC (2011). Alpha-methyl-L-tryptophan: mechanisms for tracer localization of epileptogenic brain regions. Biomark Med 5: 567–575.
13. Conn CS, Qian SB (2011). mTOR signaling in protein homeostasis: less is more? Cell Cycle 10: 1940–1947.
14. Coothankandaswamy V, Elangovan S, Singh N, Prasad PD, Thangaraju M, Ganapathy V (2013). The plasma membrane transporter SLC5A8 suppresses tumour progression through depletion of survivin without involving its transport function. Biochem J 450: 169–178.
15. Crnogorac-Jurcevic T, Chelala C, Barry S, Harada T, Bhakta V, Lattimore S et al. (2013). Molecular analysis of precursor lesions in familial pancreatic cancer. PLoS One 8: e54830.
16. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
17. Donahue TR, Tran LM, Hill R, Li Y, Kovochich A, Calvopina JH et al. (2012). Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res 18: 1352–1363.
18. Ganapathy V (2012). Protein digestion and absorption. In: Johnson LR, Ghishan FK, Kunitz JD et al. (eds). Physiology of the Gastrointestinal Tract. Academic Press: London, pp. 1595–1623.
19. Ganapathy ME, Ganapathy V (2005). Amino acid transporter ATB0,+as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord 5: 357–364.
20. Ganapathy V, Inoue K, Prasad PD, Ganapathy ME (2004). Cellular uptake of amino acids: system and regulation. In: Cynober LA (ed). Metabolic and Therapeutic Aspects of Amino Acids in Clinical Nutrition, CRC Press: Boca Raton, FL, pp. 63–78.
21. Ganapathy V, Thangaraju M, Prasad PD (2009). Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 121: 29–40.
22. Gupta N, Miyauchi S, Martindale RG, Herdman AV, Podolsky R, Miyake K et al. (2005). Upregulation of the amino acid transporter ATB0,+(SLC6A14) in colorectal cancer and metastasis in humans. Biochim Biophys Acta 1741: 215–223.
23. Gupta N, Prasad PD, Ghamande S, Moore-Martin P, Herdman AV, Martindale RG et al. (2006). Up-regulation of the amino acid transporter ATB0,+(SLC6A14) in carcinoma of the cervix. Gynecol Oncol 100: 8–13.
24. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J (1998). Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 273: 14484–14494.
25. Hiraoka N, Yamazaki-Itoh R, Ino Y, Mizuguchi Y, Yamada T, Hirohashi S et al. (2011). CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology 140: 310–321.
26. Hutson RG, Warskulat U, Haussinger D, Kilberg MS (1996). An example of nutrient control of gene expression: amino acid-dependent regulation of asparagine synthetase. Clin Nutr 15: 327–331.
27. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H et al. (2011). CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system x−cand thereby promotes tumor growth. Cancer Cell 19: 387–400.
28. Jewell JL, Guan KL (2013). Nutrient signaling to mTOR and cell growth. Trends Biochem Sci 38: 233–242.
29. Jewell JL, Russell RC, Guan KL (2013). Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol 14: 133–139.
30. Jousse C, Bruhat A, Fafournoux P (1999). Amino acid regulation of gene expression. Curr Opin Clin Metab Care 2: 297–301.
31. Karunakaran S, Umapathy NS, Thangaraju M, Hatanaka T, Itagaki S, Munn DH et al. (2008). Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy. Biochem J 414: 343–355.
32. Karunakaran S, Ramachandran S, Coothankandaswamy V, Elangovan S, Babu E, Periyasamy-Thandavan S et al. (2011). SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer. J Biol Chem 286: 31830–31838.
33. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
34. Levine B, Klionsky DJ (2004). Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6: 463–477.
35. Loewith R, Hall MN (2011). Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics 189: 1177–1201.
36. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
37. Miyazawa M, Yasuda M, Fujita M, Kajiwara H, Hirabayashi K, Takekoshi S et al. (2009). Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int 59: 19–27.
38. Muller A, Chiotellis A, Keller C, Ametamey SM, Schibli R, Mu L et al. (2014). Imaging tumour ATB0,+transport activity by PET with the cationic amino acid O-2((2-[(18)F]fluoroethyl)methyl-amino)ethyltyrosine. Mol Imaging Biol 16: 412–420.
39. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B et al. (2009). Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136: 521–534.
40. Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W et al. (2009). FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 16: 259–266.
41. Penheiter AR, Erdogan S, Murphy SJ, Hart SN, Felipe Lima J, Rakhshan Rohakhtar F et al. (2015). Transcriptomic and immunohistochemical profiling of SLC6A14 in pancreatic ductal adenocarcinoma. Biomed Res Int : 593572. doi:10.1155/2015/593572.
42. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 44: D1054–D1068.
43. Stroka KM, Konstantopoulos K (2014). Physical biology in cancer. 4. Physical cues guide tumor cell adhesion and migration. Am J Physiol Cell Physiol 306: C98–C109.
44. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A et al. (2013). Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24: 450–465.
45. Ward PS, Thompson CB (2012). Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21: 297–308.
46. Ying JE, Zhu LM, Liu BX (2012). Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol 18: 736–745.
47. Zhang G, He P, Tan H, Budhu A, Gaedcke J, Ghadimi BM et al. (2013). Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res 19: 4983–4993.
48. Zoncu R, Efeyan A, Sabatini DM (2011). mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21–35.